RGS Protein Function in Cardiac Physiology
RGS 蛋白在心脏生理学中的功能
基本信息
- 批准号:7391575
- 负责人:
- 金额:$ 32.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-08-15 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:ActinsAgonistAngiotensin IIBlood PressureBreedingCardiacCardiac MyocytesCell SizeCultured CellsDevelopmentDinoprostDisruptionEndothelin-1EvaluationExerciseFibroblast Growth Factor 2Functional disorderFundingGTP-Binding Protein RegulatorsGTP-Binding ProteinsGTPase-Activating ProteinsGene ExpressionGenerationsGenesGrowthHeartHeart DiseasesHeart HypertrophyHeterotrimeric GTP-Binding ProteinsHumanHypertrophyKnockout MiceLeucineLigandsMeasurementMediatingModelingMusNeonatalPathogenesisPhasePhenylephrinePhysiologicalPhysiologyPlayPrincipal InvestigatorProtein OverexpressionRGS Family GeneRGS ProteinsRGS2 geneRGS3 geneRattusRegulationResearch PersonnelRoleSignal TransductionSmall Interfering RNAStimulusStructureTestingTherapeutic AgentsThinkingextracellularhuman RGS2 proteinhuman RGS3 proteinin vivoknock-downnovel therapeuticsoutcome forecastpolymerizationpressureprogramsprotein activationprotein functionresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): Cardiac hypertrophy in humans is frequently associated with a poor prognosis. In cultured rat cardiac myocytes, ligands such as phenylephrine, endothelin-1, angiotensin II, and prostaglandin F2alpha promote a hypertrophic response. There is evidence that the action of these ligands on cultured cells mimics cardiac hypertrophy in humans. Most agonists that cause cultured cardiomyocytes to hypertrophy signal via heterotrimeric G proteins. Regulator of G protein signaling (RGS) proteins are GTPase activating proteins (GAPs) that deactivate asubunits of heterotrimeric G proteins. The main aim of this proposal is to investigate the physiologic role of RGS proteins in the regulation of cardiac hypertrophic growth program. The central hypothesis is that RGS proteins determine the responsiveness of cardiac myocytes to extracellular stimuli, and that RGS gene expression is increased as an adaptive mechanism to limit Gprotein- mediated signal transduction. In the original funding period, we demonstrated that RGS proteins are present in heart, that RGS3 and RGS4 gene expression is responsive to external stimuli, that cardiacspecific overexpression of RGS4 in mice blocks pressure overload- and exercise-induced cardiac hypertrophy, and that RGS4 is a GAP for Gq in the in vivo heart. Despite these findings, many questions remain about the role of RGS proteins in heart disease. In the next phase of this project, we propose to investigate the specific role of RGS2, RGS3, and RGS4, in cardiac myocyte hypertrophy by use of a "knock-down" strategy in cultured cells. Second, we investigate the specific role of RGS4 in pressure overload- and exercise-induced cardiac hypertrophy by use of mice with both whole-body and cardiacspecific targeted disruption of this gene. Third, we investigate the specific role of RGS3 in pressure overload- and exercise-induced cardiac hypertrophy by use of mice with whole-body targeted disruption of this gene. These experiments will help define the role of RGS proteins in the pathogenesis of cardiac hypertrophy and contractile dysfunction and may provide important information for the development of novel therapeutic agents.
描述(由申请人提供):人类心脏肥大经常与预后不良有关。在培养的大鼠心肌细胞中,苯肾上腺素,内皮素-1,血管紧张素II和前列腺素F2alpha等配体促进了肥大反应。有证据表明,这些配体对培养细胞的作用模仿了人类的心脏肥大。大多数通过异三聚体G蛋白引起肥大信号的培养心肌细胞的激动剂。 G蛋白信号传导(RGS)蛋白的调节剂是GTPase激活蛋白(GAPS),可将杂物二聚体G蛋白的抗育蛋白失效。该提案的主要目的是研究RGS蛋白在心脏肥大生长计划调节中的生理作用。中心假设是RGS蛋白决定了心肌细胞对细胞外刺激的反应性,并且RGS基因表达被增加作为限制Gprotein介导的信号转导的一种适应性机制。在最初的资金期间,我们证明了RGS蛋白质存在于心脏中,RGS3和RGS4基因表达对外部刺激有反应,RGS4的心脏特异性过表达会阻止压力超负荷和运动诱导的心脏肥大,并且RGS4对于GQ中的GQ是Vivo Heart in In vivo Heart in In vivo Heart in In vivo Heart a Heart in In vivo Heart a Heart in In vivo。尽管有这些发现,但关于RGS蛋白在心脏病中的作用仍然存在许多问题。在该项目的下一个阶段,我们建议通过在培养细胞中使用“敲低”策略来研究心肌肥大中RGS2,RGS3和RGS4的特定作用。其次,我们通过使用具有全身和心脏特异性靶向靶向破坏的小鼠,研究了RGS4在压力过载和运动诱导的心脏肥大中的特定作用。第三,我们通过使用该基因的全身靶向破坏的小鼠,研究了RGS3在压力超负荷和运动诱导的心肥大中的特定作用。这些实验将有助于定义RGS蛋白在心脏肥大和收缩功能障碍的发病机理中的作用,并可能为开发新型治疗剂提供重要信息。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTHONY JUSTIN MUSLIN其他文献
ANTHONY JUSTIN MUSLIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTHONY JUSTIN MUSLIN', 18)}}的其他基金
ALTERED CARDIAC MYOCYTE SIGNALING IN DIABETIC MYOCARDIUM AND FUNCTIONAL SEQUELAE
糖尿病心肌中心肌细胞信号传导的改变和功能性后遗症
- 批准号:
7651703 - 财政年份:2009
- 资助金额:
$ 32.64万 - 项目类别:
MAP Kinase and AKT Signaling in Congestive Heart Failure
充血性心力衰竭中的 MAP 激酶和 AKT 信号转导
- 批准号:
7078575 - 财政年份:2005
- 资助金额:
$ 32.64万 - 项目类别:
MAP Kinase and AKT Signaling in Congestive Heart Failure
充血性心力衰竭中的 MAP 激酶和 AKT 信号转导
- 批准号:
6967075 - 财政年份:2005
- 资助金额:
$ 32.64万 - 项目类别:
MAP Kinase and AKT Signaling in Congestive Heart Failure
充血性心力衰竭中的 MAP 激酶和 AKT 信号转导
- 批准号:
7433293 - 财政年份:2005
- 资助金额:
$ 32.64万 - 项目类别:
MAP Kinase and AKT Signaling in Congestive Heart Failure
充血性心力衰竭中的 MAP 激酶和 AKT 信号转导
- 批准号:
7626492 - 财政年份:2005
- 资助金额:
$ 32.64万 - 项目类别:
MAP Kinase and AKT Signaling in Congestive Heart Failure
充血性心力衰竭中的 MAP 激酶和 AKT 信号转导
- 批准号:
7233975 - 财政年份:2005
- 资助金额:
$ 32.64万 - 项目类别:
G protein coupling of lipid metabolism in diabetic heart
G蛋白偶联糖尿病心脏脂质代谢
- 批准号:
6591380 - 财政年份:2002
- 资助金额:
$ 32.64万 - 项目类别:
相似国自然基金
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
- 批准号:82303819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
负载自组装型非核苷类STING激动剂的亚精胺水凝胶用于抗肿瘤免疫治疗及机制研究
- 批准号:82303561
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向SIRT3小分子激动剂调控三阴性乳腺癌细胞自噬和免疫微环境的机制研究
- 批准号:82373193
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于OSMAC-GNPS分析策略的蚂蚱内生真菌Aspergillus sp.中新颖泛PPAR激动剂的发现及治疗NASH研究
- 批准号:82304340
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
探究FSP1激动剂在治疗肾缺血再灌注损伤中的分子机理与应用
- 批准号:82304600
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Interventions Against the Molecular Etiology of BMPR2-induced PAH
针对 BMPR2 诱导的 PAH 分子病因学的干预措施
- 批准号:
10352413 - 财政年份:2019
- 资助金额:
$ 32.64万 - 项目类别:
Role of Vascular Smooth Muscle Bcl11b in Arterial Stiffness
血管平滑肌 Bcl11b 在动脉僵硬中的作用
- 批准号:
9922405 - 财政年份:2018
- 资助金额:
$ 32.64万 - 项目类别:
Role of Vascular Smooth Muscle Bcl11b in Arterial Stiffness
血管平滑肌 Bcl11b 在动脉僵硬中的作用
- 批准号:
10339393 - 财政年份:2018
- 资助金额:
$ 32.64万 - 项目类别:
Role of Vascular Smooth Muscle Bcl11b in Arterial Stiffness
血管平滑肌 Bcl11b 在动脉僵硬中的作用
- 批准号:
10092210 - 财政年份:2018
- 资助金额:
$ 32.64万 - 项目类别: